血浆可溶性fms样酪氨酸激酶1与胎盘生长因子比值中位数倍数11.5可预测检测后2周内重度子痫前期
美国18中心队列研究纳入543例23至35周妊娠高血压住院患者,血浆可溶性fms样酪氨酸激酶1与胎盘生长因子比值中位数倍数≥11.5预测2周内重度子痫前期灵敏度90.6%、特异度76.9%,曲线下面积0.91,独立关联调整发病率比9.08。
要点
- 比值中位数倍数≥11.5预测2周内重度子痫前期灵敏度90.6%、特异度76.9%、阴性预测值94.3%。
- 比值≥11.5组重度子痫前期66.0% vs 比值<11.5组5.7%(P<.001)。
- 比值≥11.5独立关联重度子痫前期调整发病率比9.08(95%CI 6.11-14.06)。
核心结论
- 住院高血压孕妇23至35周妊娠时血浆可溶性fms样酪氨酸激酶1与胎盘生长因子比值≥11.5中位数倍数可预测2周内进展为重度子痫前期和重度不良围产结局。
研究设计与样本
- 美国18中心队列研究,纳入23至35周妊娠高血压住院患者543例。
- 对入组时母体血浆生物标志物、最高收缩压或舒张压及实验室值进行受试者工作特征曲线分析。
- 比较曲线下面积,拟合准泊松回归模型估计相对风险。
主要发现
- 543例中2周内重度子痫前期发生率为33.1%(n=180)。
- 比值中位数倍数≥11.5组vs<11.5组:重度子痫前期66.0% vs 5.7%(P<.001),重度不良母体结局复合终点8.11% vs 2.7%(P=.006),重度不良围产结局复合终点41.3% vs 10.14%(P=.001)。
- 比值≥11.5中位数倍数独立关联重度子痫前期调整发病率比9.08(95%CI 6.11-14.06,P<.001)和重度不良围产结局复合终点调整发病率比9.42(95%CI 6.36-14.53,P<.001),但与重度不良母体结局复合终点无显著关联(调整发病率比2.20,95%CI 0.95-5.54,P=.08)。
- 比值中位数倍数的曲线下面积0.91(95%CI 0.89-0.94)显著高于任一单独血浆生物标志物或其他参数(P<.001),但与比值绝对值无显著差异。
关键数值与推荐
- 比值中位数倍数11.5截断值预测2周内重度子痫前期:灵敏度90.6%、特异度76.9%、阳性预测值66.0%、阴性预测值94.3%、阳性似然比3.91、阴性似然比0.12、准确率81.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiogenic imbalances, characterized by an excess of antiangiogenic factors (soluble fms-like tyrosine kinase 1) and reduced angiogenic factors (vascular endothelial growth factor and placental growth factor), contribute to the mechanisms of disease in preeclampsia. The ratio of soluble fms-like tyrosine kinase 1 to placental growth factor has been used as a biomarker for preeclampsia, but the cutoff values may vary with gestational age and assay platform. OBJECTIVE: This study aimed to compare multiples of the median of the maternal plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio, soluble fms-like tyrosine kinase 1, placental growth factor, and conventional clinical and laboratory values in their ability to predict preeclampsia with severe features. STUDY DESIGN: We conducted a cohort study across 18 United States centers involving hospitalized individuals with hypertension between 23 and 35 weeks' gestation. Receiver operating characteristic curve analyses of maternal plasma biomarkers, highest systolic or diastolic blood pressures, and laboratory values at enrollment were performed for the prediction of preeclampsia with severe features. The areas under the curve were compared, and quasi-Poisson regression models were fitted to estimate relative risks. The primary outcome was preeclampsia with severe features within 2 weeks of enrollment. Secondary outcomes were a composite of severe adverse maternal outcomes (elevated liver enzymes, low platelets count, placental abruption, eclampsia, disseminated intravascular coagulation, and pulmonary edema) and a composite of severe adverse perinatal outcomes (birth weight below the third percentile, very preterm birth [<32 weeks' gestation], and fetal or neonatal death). RESULTS: Of the 543 individuals included in the study, preeclampsia with severe features within 2 weeks was observed in 33.1% (n=180) of them. A receiver operating characteristic curve-derived cutoff of 11.5 multiples of the median for the soluble fms-like tyrosine kinase 1 to placental growth factor plasma ratio provided good sensitivity (90.6%), specificity (76.9%), positive predictive value (66.0%), negative predictive value (94.3%), positive likelihood ratio (3.91), negative likelihood ratio (0.12), and accuracy (81.4%) for preeclampsia with severe features within 2 weeks. This cutoff was used to compare test positive cases (≥ cutoff) and test negative cases (< cutoff). Preeclampsia with severe features (66.0% vs 5.7%; P<.001) and composites of severe adverse maternal (8.11% vs 2.7%; P=.006) or perinatal (41.3% vs 10.14%; P=.001) outcomes within 2 weeks were more frequent in test positive cases than in test negative cases. A soluble fms-like tyrosine kinase 1 to placental growth factor plasma ratio ≥11.5 multiples of the median was independently associated with preeclampsia with severe features (adjusted incidence rate ratio, 9.08; 95% confidence interval, 6.11-14.06; P<.001) and a composite of severe adverse perinatal outcomes (adjusted incidence rate ratio, 9.42; 95% confidence interval, 6.36-14.53; P<.001) but not with a composite of severe adverse maternal outcomes (adjusted incidence rate ratio, 2.20; 95% confidence interval, 0.95-5.54; P=.08). The area under the curve for the soluble fms-like tyrosine kinase 1 to placental growth factor plasma ratio in multiples of the median (0.91; 95% confidence interval, 0.89-0.94) for preeclampsia with severe features within 2 weeks was significantly higher (P<.001 for all comparisons) than either plasma biomarker alone or any other parameter with the exception of absolute soluble fms-like tyrosine kinase 1 to placental growth factor plasma ratio values. CONCLUSION: A soluble fms-like tyrosine kinase 1 to placental growth factor plasma ratio ≥11.5 multiples of the mean among hospitalized patients with hypertension between 23 and 35 week's gestation predicts progression to preeclampsia with severe features and severe adverse perinatal outcomes within 2 weeks.
引用
- Espinoza J, Calsavara VF, Kilpatrick S, et al. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. Am J Obstet Gynecol. 2024. PMID: 38825028. doi:10.1016/j.ajog.2024.05.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。